Replies to post #43 on Equity Field Notes from temporal sources

[DanWebzster]

EGRX is at earliest a H-2 2018 story.

8/18 Fulvestrant Ph3 study will be read out. This is Eagle's largest pipeline opty. It's administration benefits may make it
an attractive target for Sanofi. By the time it could be approved
in 2019, generics will have eroded SNY revenues for this compound.

12/18 Ryanodex Ph3 exertional heat stroke data will be read out, unless there is another stampede at hajj.

8/18 If there is another stampede at hajj, this trial is screwed. As for myself, I will be praying to the gods of population control, holding my breath and crossing my toes for another stampede.